Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based Transgene Biotek (Transgene) has said that a new drug for liver cancer developed by its scientists has demonstrated improved efficacy in the latest animal studies. This corroborates earlier data gathered from the in-vitro studies.
Subscribe to our email newsletter
Transgene has employed a novel gene silencing (within RNAi platform) technology to develop this drug.
The technology involves highly selective knock-down of specific liver cancer producing gene targets, which has demonstrated remarkable regression of the tumours in the animal studies, said the company.
Unlike Transgene’s new hepatic cancer drug, traditional drugs used in cancer chemotherapy are non-selective, and induce DNA damage leading to tumor relapse.
Transgene has been involved in the development of technology for different bio-pharmaceuticals, recombinant vaccines and therapeutics.